drugset / Trial / NCT02327273

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

NCT02327273 ↗

Phase 1 Completed 88 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety profile, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) following single and multiple oral doses of BMS-963272 in healthy subjects.

Timeline

Start
2014-10
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-963272 Small molecule — Oral

Indications

No indication recorded.